Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Meet the CEO. Jared Kelly has been CEO of Oncolytics since June 2025.</li><li>He is a transactional lawyer by training who previously served as head of legal and corporate strategy at Ambrx Biopharma, where he played a central role in the company’s $2-billion sale to Johnson &amp; Johnson, and subsequently advised a number of public and private drug development companies.</li><li>Before moving into biotech operating roles, he spent roughly a dozen years as a transactional lawyer advising biotech companies and strategic acquirers on IPOs, public company M&amp;A, buyouts, and licensing deals, at firms including Lowenstein Sandler LLP and Kirkland &amp; Ellis LLP.</li></ul>

Meet the CEO. Jared Kelly has been CEO of Oncolytics since June 2025.He is a transactional lawyer by training who previously served as head of legal and corporate strategy at Ambrx Biopharma, where he played a central role in the company’s $2-billion sale to Johnson &amp; Johnson, and subsequently advised a number of public and private drug development companies.Before moving into biotech operating roles, he spent roughly a dozen years as a transactional lawyer advising biotech companies and strategic acquirers on IPOs, public company M&amp;A, buyouts, and licensing deals, at firms including Lowenstein Sandler LLP and Kirkland &amp; Ellis LLP.

WTR Healthcare Happenings Podcast Recap : Oncolytics Biotech Inc. (ONCY)